Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
10.1056/NEJMoa2110956
Saved in:
Main Authors: | Pitt, Bertram, Filippatos, Gerasimos, Agarwal, Rajiv, Anker, Stefan D, Bakris, George L, Rossing, Peter, Joseph, Amer, Kolkhof, Peter, Nowack, Christina, Schloemer, Patrick, Ruilope, Luis M, FIGARO-DKD investigators |
---|---|
Other Authors: | MEDICINE |
Format: | Article |
Language: | English |
Published: |
MASSACHUSETTS MEDICAL SOC
2023
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/246025 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Language: | English |
Similar Items
-
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
by: Bakris, George L, et al.
Published: (2023) -
Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes
by: George L. Bakris, et al.
Published: (2022) -
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes
by: Filippatos, Gerasimos, et al.
Published: (2022) -
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
by: Anantharaman, Vathsala, et al.
Published: (2023) -
A myriad of electrocardiographic findings associated with digoxin use
by: Djohan, Andie Hartanto, et al.
Published: (2022)